K Mikecz Selected Research

Aggrecans (Aggrecan)

1/2014	Proteoglycan aggrecan conducting T cell activation and apoptosis in a murine model of rheumatoid arthritis.
4/2011	Osteoarthritis-like damage of cartilage in the temporomandibular joints in mice with autoimmune inflammatory arthritis.
7/2007	Aggrecanolysis in human osteoarthritis: confocal localization and biochemical characterization of ADAMTS5-hyaluronan complexes in articular cartilages.
7/2005	A longitudinal study on an autoimmune murine model of ankylosing spondylitis.
4/2004	Disease-associated qualitative and quantitative trait loci in proteoglycan-induced arthritis and collagen-induced arthritis.
8/2002	Continuous nasal administration of antigen is critical to maintain tolerance in adoptively transferred autoimmune arthritis in SCID mice.
3/2001	Variations in susceptibility to proteoglycan-induced arthritis and spondylitis among C3H substrains of mice: evidence of genetically acquired resistance to autoimmune disease.
4/2000	Complex pattern of Th1 and Th2 activation with a preferential increase of autoreactive Th1 cells in BALB/c mice with proteoglycan (aggrecan)-induced arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

K Mikecz Research Topics

Disease

15	Arthritis (Polyarthritis) 01/2014 - 04/2000
7	Rheumatoid Arthritis 01/2014 - 04/2000
3	Autoimmune Diseases (Autoimmune Disease) 01/2014 - 03/2001
2	Osteoarthritis 08/2009 - 07/2007
2	Spondylitis 07/2005 - 03/2001
2	Experimental Arthritis 04/2004 - 12/2001
2	Inflammation (Inflammations) 12/2001 - 04/2000
1	Spondylarthropathies 07/2005
1	Edema (Dropsy) 11/2001
1	Leiomyosarcoma 10/2000
1	Psoriasis (Pustulosis Palmaris et Plantaris) 10/2000
1	Hypersensitivity (Allergy) 09/2000

Drug/Important Bio-Agent (IBA)

13	Proteoglycans (Proteoglycan)IBA 01/2014 - 04/2000
8	Aggrecans (Aggrecan)IBA 01/2014 - 04/2000
2	EpitopesIBA 01/2014 - 02/2012
2	AutoantigensIBA 01/2014 - 08/2002
2	CytokinesIBA 04/2011 - 04/2000
2	AntigensIBA 08/2002 - 11/2001
2	Hyaluronic Acid (Hyaluronan)IBA 12/2001 - 11/2001
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2014
1	DNA (Deoxyribonucleic Acid)IBA 06/2012
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 02/2012
1	AntibodiesIBA 02/2012
1	Proteins (Proteins, Gene)FDA Link 02/2012
1	Glucosamine (Dona)IBA 08/2009
1	aggrecanaseIBA 07/2007
1	Collagen Type II (Type II Collagen)IBA 08/2002
1	Cell Surface ReceptorsIBA 12/2001
1	etaracizumabIBA 10/2000
1	Peptides (Polypeptides)IBA 10/2000
1	VitronectinIBA 10/2000
1	Biocompatible Materials (Biomaterials)IBA 09/2000
1	MetalsIBA 09/2000
1	Immunoglobulin G (IgG)IBA 04/2000

Therapy/Procedure

1	Intranasal Administration 08/2002
1	Intravenous Injections 11/2001
1	Therapeutics 10/2000
1	Arthroplasty 09/2000
1	Replacement Arthroplasty 09/2000